Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...

In the swiftly evolving field of artificial intelligence (AI), the technology's capability to revolutionize care processes in ...

When Amanda Smith walked into the kitchen one night in 2015 to warm up a bottle for her four-month-old daughter, she couldn’t make out the numbers on the microwave. They were blurry. They’d never been ...

Supported by an unrestricted grant from INCYTE. In this webinar Julie Ann Lough is joined by three experts in the fields of oncology and pathology: Albrecht Stenzinger, Nicola Normanno and Angela ...

For decades, we trusted big pharmaceutical companies to deliver the cures of the future—blockbuster drugs, cutting-edge therapies, vaccines that changed history, and lives saved. But that model is ...

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies. Management of newly diagnosed acute ...

Curative-intent multimodality treatment—combining local treatments such as surgery or radiotherapy with systemic therapy—is the cornerstone of care in stage II–III non-small cell lung cancer (NSCLC).

For this week’s Open Questions column, Dhruv Khullar is filling in for Joshua Rothman. When David Fajgenbaum was a twenty-five-year-old medical student, at the University of Pennsylvania, he started ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...